Class I - There is evidence
and/or general agreement that patients undergoing PCI
should be given GP IIb/IIIa inhibitors in the following
setting: |
Abciximab,
eptifibatide, or tirofiban without clopidogrel for a
non-ST elevation acute coronary syndrome (ACS)* |
Class IIa - The weight of
evidence or opinion is in favor of the usefulness of GP
IIb/IIIa inhibitors in patients undergoing PCI in the
following settings: |
Abciximab,
eptifibatide, or tirofiban with clopidogrel for a non-ST
elevation ACS.* |
Abciximab as
early as possible for ST elevation MI. |
Abciximab,
eptifibatide, or tirofiban at the time of elective PCI
with stent placement. |
Class IIb - The weight of
evidence or opinion is less well established for the
usefulness of GP IIb/IIIa inhibitors in patients
undergoing PCI in the following setting: |
Eptifibatide
or tirofiban for ST elevation
MI. |